la fase 2 del H7N9
(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant
https://clinicaltrials.gov/ct2/show/NCT02078674?term=novavax&rank=
a fecha 30 Septiembre: This study has been completed.Resultados pronto .... :) NVAX
Erdys, el incremento de ventas en Q2 de Prevnar ha sido significativo este año debido al incremento en ventas sobre adultos. Aunque no saco el dato especifico para mauores de 65 años.
http://www.fiercevaccines.com/story/pfizers-us-prevnar-13-sales-jump-87-q2/2015-07-29
"The world's biggest vaccine by sales--Prevnar 13--just keeps getting bigger. And in doing so, the shot helped Pfizer (PFE) notch 44% vaccines growth for the second quarter as the unit saw sales grow from $1.09 billion in last year's Q2 to $1.58 billion during the period this year.
For the quarter, the superstar pneumococcal disease-blocker notched a U.S. sales increase of 87% versus the same period last year, a jump Pfizer CEO Ian Read attributed to "continued strong uptake" in U.S. adults. Last August, the vaccine received a favorable CDC committee recommendation for universal use in the 65-and-over age range."
Y segun esto, entre Julio 2013-Mayo 2014, esta es la estadistica de personas vacunadas de la gripe
http://www.cdc.gov/flu/fluvaxview/coverage-1314estimates.htm#estimated
- Children (6 months through 17 years) and 42.4 million
- Adults (≥18 years), for an estimated 100.8 million
No he logrado todavia sacar la estadistica de las vacunadas mayores de 65 años....
GRIPE
CYTX
Esto quiere decir que se ha informado a la SEC que se ha comprado más de un 5% de la compañía. Pero no se sí esto será bueno o malo, o seguiremos igual.
es una inversion significativa d eun fondo , malo no sera.
CYTX
Como es habitual, hasta que se haga publica la nota de Bionvest solo puedo repetir los comentarios usanos que leo al respecto de la de este Domingo.
Se reiteran en el PO a 20$ y en lo dicho hasta la fecha sobre los buenos resultados obtenidos, incluidos los de embarazadas. Utilizan frases como "The value of NVAX continue to rise dramatically" y hacen referencia al único analista cuya evaluacion no fue positiva.
NVAX
Venga, va:
IBB 325 o mas bien 330 .... de camino a los 35x
estoy de buen humor
In a research report released this morning, Cantor analyst Daniel Brims reiterated a Buy rating on shares ofThreshold Pharmaceuticals, Inc. (NASDAQ:THLD), with a $14 price target, after spending a day with the company’s management.
Brims observed, “Management is continuing to guide for both the Merck KGaA-run pancreatic trial and THLD-run Sarcoma trial to read out around YE:15, with top-line data potentially released simultaneously and full data being presented at scientific meetings. THLD has begun drafting the NDA, and we believe submission will occur by MID:16 assuming positive trial outcomes. We expect evo to receive priority review, with a potential approval and launch around YE:16.”
THLD
